Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体，可与 PD-1 结合，从而阻断PD-1与其配体 (PD-L1 和 PL-L2) 的相互作用，从而有助于恢复内源性抗肿瘤 T 细胞反应。Sintilimab 可用于经典霍奇金淋巴瘤、非小细胞肺癌和食管癌的研究。
| 生物活性 | Sintilimab (IBI308) is a fully humanIgG4monoclonal antibody that binds toPD-1, thereby blocking the interaction ofPD-1with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lungcancerand oesophagealcancer[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
